Exploring Three High Growth Tech Stocks in the United States

In This Article:

The United States market has shown robust performance, climbing by 2.8% over the past week and rising 25% over the past year, with earnings forecasted to grow annually by 15%. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

24.13%

24.28%

★★★★★★

Ardelyx

25.47%

69.63%

★★★★★★

Sarepta Therapeutics

24.07%

43.17%

★★★★★★

Alnylam Pharmaceuticals

22.34%

70.30%

★★★★★★

Clene

77.61%

59.19%

★★★★★★

TG Therapeutics

34.86%

56.98%

★★★★★★

Alkami Technology

21.99%

102.65%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 238 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Incyte

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for hematology/oncology and inflammation and autoimmunity globally, with a market cap of approximately $13.47 billion.

Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.08 billion. The company focuses on therapeutics for hematology/oncology and inflammation and autoimmunity across the U.S. and international markets.

Incyte's recent advancements underscore its commitment to innovation, particularly with the promising results from the Phase 3 POD1UM-304 trial of Zynyz® in treating non-small cell lung cancer, showing a notable improvement in median overall survival rates. This progress is crucial as it not only enhances Incyte’s portfolio but also solidifies its position in oncology therapeutics. Financially, Incyte has adjusted its revenue guidance upwards to $2.74 billion to $2.77 billion for 2024, reflecting confidence in its core products like Jakafi amidst a competitive market landscape. Despite some setbacks in other trials, such as the pausing of enrollment for INCB000262 due to preclinical findings, Incyte's strategic focus on high-stakes oncology treatments and robust R&D investment—which remains a significant part of their expenditure—positions it uniquely within the biotech sector for potential growth and patient impact.

NasdaqGS:INCY Revenue and Expenses Breakdown as at Dec 2024
NasdaqGS:INCY Revenue and Expenses Breakdown as at Dec 2024

Super Micro Computer

Simply Wall St Growth Rating: ★★★★★★